In 2024, IBM spent 7.48 billion U.S. dollars on research, development, and engineering. One of the most prolific research companies in existence, IBM is one of the companies with the most patents granted to them in the United States. Even though the American company is granted thousands of patents each year, IBM is still challenged to continuously develop innovative products and services in a quickly changing technology industry. Much of IBM’s projects in development are related to hybrid cloud solutions, AI, blockchain, and quantum computing.

The graph shows the changes in the impact factor of ^ and its corresponding percentile for the sake of comparison with the entire literature. Impact Factor is the most common scientometric index, which is defined by the number of citations of papers in two preceding years divided by the number of papers published in those years.

The Americas region is IBM’s greatest source of revenue with over 31 billion U.S. dollars generated in the region - around 50 percent of the company’s overall revenue. IBM's global revenue declined in the decade following 2011, with the company struggling to adapt to shifting industry trends. IBM’s investments in the future Along with many other companies in the tech industry, IBM is in a period of transition from a legacy business in the technology sector to adapting its product offerings for a changing industry. It is regaining lost ground from prior underinvestment in cloud services and applications by purchasing and investing in innovative companies in the field, as well as refocusing its own research and development expenses on new and emerging products and technologies. In 2019, IBM acquired enterprise software company Red Hat, the world’s largest provider of open-source software solutions for 34 billion U.S. dollars. Much of IBM’s research and development is in the direction of hybrid cloud, blockchain, quantum computing, and AI, in hopes to kick start growth and reverse the trend of declining revenues. Of these, quantum computing is a promising way for IBM to be at the forefront of the world’s fastest and most powerful computing devices.

List of Top Institutions of IBM Journal of Research and Development sorted by citations.

In 2024, IBM’s Software segment generated over 27 billion U.S. dollars of the company’s revenue, which for 2024 stood at around 62 billion U.S. dollars. In 2016, IBM first changed its segment reporting to reflect the company’s shift away from being a hardware, software and services company, and towards becoming a cognitive solutions and cloud platform company. In the fourth quarter of 2021, the company changed its segment reporting again, to align it better with the company's platform centric approach to hybrid cloud and AI. Reorganization of IBM's business operations The change in business segment reporting followed IBM’s pursuit of management system and organizational changes. The company spun off its infrastructure services business into a separate company, Kyndryl. The new classification of business segments is based on multiple factors, such as the homogeneity of products, technologies, and the client base. The business is now organised into software, consulting, infrastructure, financing and other segments. Moving to the hybrid cloud One of IBM’s responses to its declining revenue is restructuring some of their business, moving into areas like cloud, blockchain, and artificial intelligence. The company looks to address its underinvestment in cloud by developing software and platform products. For example, its platform IBM Cloud aims to help customers shift their operations to the cloud environments. In early 2019, IBM acquired open source technology company Red Hat, which offers a hybrid cloud platform. As a major and innovative player in the industry, IBM has consistently spendt at least 5 billion U.S. dollars on research and development, such as on advances in quantum computing and artificial intelligence.

This graph shows how the impact factor of ^ is computed. The left axis depicts the number of papers published in years X-1 and X-2, and the right axis displays their citations in year X.

List of Top Authors of IBM Journal of Research and Development sorted by citations.

Credit report of Ibm Deutschland Research & Development Gmbh contains unique and detailed export import market intelligence with it's phone, email, Linkedin and details of each import and export shipment like product, quantity, price, buyer, supplier names, country and date of shipment.

Im Jahr 2024 betrugen die Ausgaben für Forschung und Entwicklung von IBM rund *** Milliarden US-Dollar. Der IT-Konzern profitierte zuletzt besonders vom weltweiten KI-Boom und möchte in Zukunft vermehrt in Künstliche Intelligenz investieren.

The cloud-based drug discovery platform market is booming, projected to reach $2.801 billion by 2025 with an 11.3% CAGR. This report analyzes market drivers, trends, restraints, and key players like IBM and Accenture, offering insights into this rapidly evolving sector. Explore the future of pharmaceutical R&D.

The Inclusion Body Myositis (IBM) therapeutics market is experiencing significant growth, driven by the increasing prevalence of this debilitating neuromuscular disorder and the unmet medical needs of affected patients. While precise market size data for 2025 is unavailable, considering the typical market size of rare disease therapeutics and extrapolating from available information on similar-sized markets, a reasonable estimate places the 2025 market value at approximately $500 million. This market is projected to exhibit a robust Compound Annual Growth Rate (CAGR) of 15% from 2025 to 2033, fueled by several key factors. These include the ongoing development of novel therapeutic approaches targeting the underlying pathological mechanisms of IBM, a rising awareness of the disease among healthcare professionals leading to improved diagnosis rates, and a growing demand for effective treatment options from patients and their caregivers. The market is segmented by drug type (including ACE-083, Aceneuramic Acid ER, ALZ-1903, UX-001P, UX-007, and others) and by end-user application (research centers, hospitals, and clinics). The North American market currently holds a significant share, due to advanced healthcare infrastructure and a higher concentration of research and development activities. However, the Asia-Pacific region is expected to witness substantial growth during the forecast period, fueled by increasing healthcare expenditure and rising disease awareness in rapidly developing economies like China and India. Competitive landscape analysis shows a growing number of pharmaceutical companies actively involved in the development and commercialization of IBM treatments, indicating a highly dynamic market. The continued rise in the aging population, a primary risk factor for IBM, is a long-term driver for market expansion. Challenges remain, however, including the lack of FDA-approved treatments specifically for IBM, difficulties in early diagnosis due to overlapping symptoms with other neuromuscular conditions, and the high cost of developing and commercializing novel therapeutics for rare diseases. Overcoming these challenges through continued research and development, improved diagnostic tools, and increased healthcare access will be crucial for driving future market growth and ultimately providing better treatment options for IBM patients.

The Inclusion Body Myositis (IBM) therapeutics market is experiencing significant growth, driven by the increasing prevalence of this debilitating neuromuscular disorder and the unmet medical needs of patients. While precise market sizing data is unavailable, considering the rarity of IBM and the high cost of potential treatments, a reasonable estimate for the 2025 market size could be around $250 million. A compound annual growth rate (CAGR) of 15% from 2025 to 2033 is plausible given the ongoing research and development efforts focused on novel therapies. Key drivers include the rising geriatric population (IBM predominantly affects older adults), increased awareness of the disease, and the limitations of current treatment options, which are primarily supportive rather than disease-modifying. Emerging trends include a shift towards targeted therapies focusing on underlying disease mechanisms, a rise in clinical trials evaluating promising drug candidates, and increased collaborations between pharmaceutical companies and research institutions. Restraints to market growth primarily include the challenges associated with developing effective therapies for a rare disease, the complexities of clinical trial design in IBM, and regulatory hurdles for drug approvals. Segmentation within the market is likely driven by drug type (e.g., small molecule inhibitors, biologics), stage of development (clinical vs. pre-clinical), and geographic region. Companies actively involved in the IBM therapeutic space, such as Acceleron Pharma Inc., KPI Therapeutics Inc., and others listed, are strategically focusing on developing innovative treatments to address this significant healthcare need. The forecast period from 2025-2033 is poised for considerable expansion within the IBM therapeutics market, fueled by continuous advancements in our understanding of disease pathogenesis and the development of promising therapeutics. The significant investment in research and development, along with the growing need for effective treatments, will likely accelerate market growth. However, the high cost of drug development and the complexities involved in bringing new therapies to market will continue to pose challenges. Given the rarity of IBM, successful market penetration will depend on robust clinical trial data demonstrating efficacy and safety, coupled with targeted marketing strategies to reach both healthcare professionals and patients. Regulatory approval pathways and pricing strategies will also play pivotal roles in shaping the future trajectory of this market. Future growth will also depend on the successful development and launch of disease-modifying therapies that can significantly improve patient outcomes, addressing the substantial unmet need currently present within the IBM therapeutic landscape.

American corporations operated a total of *** artificial intelligence (AI) R&D laboratories in Israel, as of 2020. This amounted to ** percent of global AI labs run by these companies. Google and Microsoft both owned *** such labs. Similarly, Facebook and IBM operated *** AI lab each. One possible explanation for the density of corporate-led research in the country was the high concentration of AI talent.

Eximpedia Export import trade data lets you search trade data and active Exporters, Importers, Buyers, Suppliers, manufacturers exporters from over 209 countries

The Wireless Electromagnetic Tracking System market is booming, projected to reach $1.27 billion by 2033, driven by healthcare, industrial automation, and research applications. Learn about market trends, key players (IBM, HCL, Polhemus), and future growth opportunities in this comprehensive analysis.

The ion beam machining (IBM) market is booming, projected to reach $320 million in 2025 and beyond $600 million by 2033. Discover key trends, growth drivers, and leading companies shaping this high-precision manufacturing sector. Explore market analysis and forecasts for this exciting niche.

The quantum computing chip market is poised for substantial growth, driven by escalating research and development investments, increasing government support, and the burgeoning demand for high-performance computing across diverse sectors. While precise market size figures for 2025 are not provided, considering a conservative estimate and leveraging the reported CAGR (let's assume a CAGR of 30% for illustrative purposes), a reasonable projection would place the 2025 market value in the range of $500 million to $700 million. This robust growth trajectory is anticipated to continue throughout the forecast period (2025-2033), fueled by advancements in qubit technology, improved error correction techniques, and the emergence of hybrid quantum-classical computing architectures. Major players like IBM, Google, Microsoft, and Intel are heavily investing in research and development, fostering innovation and competition within the space. Furthermore, the entry of specialized quantum computing startups, including Rigetti Computing, Xanadu, and IonQ, is injecting further dynamism into the market. The current market is fragmented, with various companies focusing on different qubit modalities (superconducting, trapped ions, photonic, etc.), leading to a diverse range of technological approaches. However, significant challenges remain. The development of fault-tolerant quantum computers is complex and costly, requiring substantial advancements in materials science, engineering, and software development. Scalability issues, qubit coherence times, and the high cost of quantum computing systems represent key restraints to broader market adoption. Despite these challenges, the long-term potential for quantum computing to revolutionize fields such as drug discovery, materials science, financial modeling, and artificial intelligence is undeniable, ultimately driving continued investment and market expansion throughout the 2020s and beyond. The market segmentation will likely see further diversification as specialized applications drive the need for niche chip designs. Regional dominance is expected to initially favor North America and Europe, given the concentration of research and development efforts in these regions, but Asia is expected to emerge as a strong contender as their investment in the field increases.

The global universal quantum computer market is poised for significant growth, driven by escalating demand across diverse sectors. While precise figures for market size in 2025 are unavailable, a reasonable estimation, considering the rapid technological advancements and substantial investments in the field, places the market value at approximately $500 million. This sector is projected to experience a robust Compound Annual Growth Rate (CAGR) of 60% from 2025 to 2033. This impressive growth is fueled by several key drivers, including the increasing sophistication of quantum algorithms for solving complex computational problems, the development of more stable and scalable quantum computers, and growing governmental and private sector funding for quantum computing research and development. Major industries like artificial intelligence, pharmaceuticals (driving medical advancements), transportation (optimizing logistics and autonomous systems), and telecommunications (enhancing network security and efficiency) are early adopters, significantly contributing to market expansion. Despite challenges like the high cost of quantum computers and the need for specialized expertise, the potential for disruptive innovation and transformative solutions across numerous fields is overcoming these limitations, propelling the market's rapid ascent. The market segmentation reveals a dynamic landscape. Adiabatic and gate-model quantum computers represent distinct architectural approaches, each with its own strengths and applications. The application-based segmentation highlights the diverse industries driving demand, with the AI industry currently leading the way due to the inherent computational power needed for machine learning and deep learning algorithms. The competitive landscape features a mix of established technology giants like IBM and Microsoft alongside innovative startups such as Rigetti and Xanadu. Geographical distribution reflects a concentration in North America and Europe, where significant research and development efforts are underway, although the Asia-Pacific region is experiencing rapid growth due to increased investments in quantum technology. The forecast period from 2025-2033 promises sustained expansion, with emerging applications and technological breakthroughs further accelerating market growth. The anticipated growth trajectory solidifies the universal quantum computer market as a highly lucrative and strategically important sector for the foreseeable future.

The General Engineering Research Efficiency Platform market is poised for significant expansion, projected to reach approximately $10,420 million in value. This robust growth is fueled by an impressive Compound Annual Growth Rate (CAGR) of 8.9% over the forecast period of 2025-2033. The primary drivers of this upward trajectory include the increasing complexity of engineering projects, the growing demand for sophisticated simulation and analysis tools, and the continuous push for faster innovation cycles across various industries. The platform's ability to streamline research workflows, enhance collaboration among engineers, and provide advanced data analytics makes it an indispensable asset for organizations aiming to maintain a competitive edge. Moreover, the ongoing digital transformation initiatives within the engineering sector are further accelerating the adoption of these efficiency platforms. The market is segmented across enterprise sizes, with Large Enterprises representing a significant portion of current adoption, driven by their extensive R&D budgets and complex project needs. However, Medium and Small Enterprises are increasingly recognizing the value proposition of these platforms, leading to their faster growth rates. Cloud-based solutions are dominating the market due to their scalability, flexibility, and cost-effectiveness, although on-premises solutions continue to hold a share, particularly for organizations with stringent data security requirements. Key players like MathWorks, Microsoft, IBM, Autodesk, and Siemens are at the forefront of innovation, offering comprehensive suites of tools and services that cater to a diverse range of engineering disciplines. Geographic expansion is also a notable trend, with North America and Europe currently leading, while the Asia Pacific region is expected to witness substantial growth due to its burgeoning manufacturing and technology sectors. This comprehensive report delves into the evolving landscape of the General Engineering Research Efficiency Platform (GEREP). Spanning a crucial Study Period from 2019 to 2033, with a Base Year of 2025 and a Forecast Period extending from 2025 to 2033, this analysis provides granular insights into market dynamics, strategic players, and future trajectories. We have meticulously analyzed the Historical Period of 2019-2024 to establish a robust foundation for our projections. The report aims to equip stakeholders with actionable intelligence to navigate and capitalize on the burgeoning opportunities within this vital technological domain.

The Artificial Intelligence (AI) Laboratory market is experiencing robust growth, driven by increasing demand for advanced AI research and development across various sectors. While precise figures for market size and CAGR aren't provided, considering the involvement of major players like IBM, Alibaba, and DiDi, and the rapid advancements in AI technologies, a reasonable estimation places the 2025 market size at approximately $5 billion USD. Considering a conservative estimate for future growth, based on industry trends and the accelerating adoption of AI in research and development, a Compound Annual Growth Rate (CAGR) of 15% from 2025 to 2033 appears plausible. This would project the market to reach approximately $17 billion USD by 2033. Key drivers include the rising need for automation, improved data analytics capabilities, and the development of cutting-edge AI algorithms for various applications, including healthcare, finance, and autonomous systems. Trends include a growing focus on edge AI, explainable AI (XAI), and the increasing adoption of cloud-based AI infrastructure. However, restraints such as high initial investment costs, data security concerns, and the ethical implications of advanced AI technologies present challenges to market expansion. The market is segmented based on application (e.g., healthcare, finance, autonomous vehicles), technology (e.g., machine learning, deep learning), and geography. The competitive landscape is characterized by a mix of established tech giants and specialized AI startups. Companies like IBM contribute through their vast research capabilities and established infrastructure, while companies like Alibaba and DiDi are leveraging AI for internal optimization and new product development. Chinese companies like Beijing Pukai Data Technology, Guangdong Teddy Intelligent Technology, and Shenzhen Youbixuan Technology demonstrate a strong regional presence, highlighting the importance of the Asian market. Companies like KnowLeGene and OpenBayes indicate a burgeoning market for specialized AI solutions. The future growth of the AI Laboratory market will heavily depend on continued technological innovation, increased government funding for AI research, and the resolution of ethical concerns surrounding AI implementation. The market offers substantial opportunities for companies able to innovate and address the unique challenges and opportunities presented by this rapidly evolving field.